438 related articles for article (PubMed ID: 12083327)
1. Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2.
Stancek D; Fuchsberger N; Oltman M; Schmeisser H; Kontsek P; Jahnová E; Hajnická V
Acta Virol; 2001; 45(5-6):287-92. PubMed ID: 12083327
[TBL] [Abstract][Full Text] [Related]
2. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
3. [Study of the relapse of patients with chronic hepatitis B undergoing first and repeated recombinant interferon-alpha therapy during long-term follow up].
Liu DL; Luo KX; Feng XR; Fu QX; Hou JL
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1840-3. PubMed ID: 17922996
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of alpha-interferon therapy of chronic hepatitis patients infected with wild type hepatitis B virus and HBEAG-minus mutant.
Husa P; Chalupa P; Stroblová H; Husová L; Slesinger P
Acta Virol; 2001; 45(5-6):293-7. PubMed ID: 12083328
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of long-term interferon therapy in chronic hepatitis B patients with HBV genotype C.
Sakai T; Shiraki K; Inoue H; Okano H; Deguchi M; Sugimoto K; Ohmori S; Murata K; Nakano T
Int J Mol Med; 2002 Aug; 10(2):201-4. PubMed ID: 12119559
[TBL] [Abstract][Full Text] [Related]
6. Individualization of interferon therapy using serum hepatitis B virus DNA to reduce viral relapse in patients with chronic hepatitis B: a randomized controlled trial.
Chung YH; Song BC; Lee GC; Shin JW; Ryu SH; Jung SA; Yoo K; Lee HC; Lee YS; Suh DJ
Eur J Gastroenterol Hepatol; 2003 May; 15(5):489-93. PubMed ID: 12702905
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.
Yuen MF; Hui CK; Cheng CC; Wu CH; Lai YP; Lai CL
Hepatology; 2001 Jul; 34(1):139-45. PubMed ID: 11431745
[TBL] [Abstract][Full Text] [Related]
8. Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission.
Zampino R; Marrone A; Karayiannis P; Cirillo G; del Giudice EM; Rania G; Utili R; Ruggiero G
Am J Gastroenterol; 2002 Sep; 97(9):2426-31. PubMed ID: 12358268
[TBL] [Abstract][Full Text] [Related]
9. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
Akhan SC; Yulugkural Z; Vahaboglu H
Chemotherapy; 2007; 53(6):402-6. PubMed ID: 17934260
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.
van Zonneveld M; Honkoop P; Hansen BE; Niesters HG; Darwish Murad S; de Man RA; Schalm SW; Janssen HL
Hepatology; 2004 Mar; 39(3):804-10. PubMed ID: 14999700
[TBL] [Abstract][Full Text] [Related]
11. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
12. [Viral co-infections in hepatitis C: HBV, HBV-C/HGV and TTV studies].
Pár A; Takács M; Brojnás J; Berencsi G; Paál M; Horányi M; Miseta A; Hegedüs G; Mózsik G; Hunyady B
Orv Hetil; 2004 May; 145(19):987-92. PubMed ID: 15181733
[TBL] [Abstract][Full Text] [Related]
13. Relationship between HBV genotypes and anti-viral therapeutic efficacy of interferon-alpha.
Ma JC; Wang LW; Li XJ; Liao YF; Hu XY; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):166-71. PubMed ID: 17374576
[TBL] [Abstract][Full Text] [Related]
14. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
[TBL] [Abstract][Full Text] [Related]
15. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial.
Villa E; Grottola A; Buttafoco P; Colantoni A; Bagni A; Ferretti I; Cremonini C; Bertani H; Manenti F
Am J Gastroenterol; 2001 Oct; 96(10):2973-7. PubMed ID: 11693335
[TBL] [Abstract][Full Text] [Related]
16. Early response to interferon alpha treatment and long-term clinical outcome in Japanese patients with chronic HBV genotype C infection.
Seo Y; Yoon S; Hamano K; Nakaji M; Yano Y; Katayama M; Ninomiya T; Hayashi Y; Kasuga M
Int J Mol Med; 2004 Jan; 13(1):75-9. PubMed ID: 14654974
[TBL] [Abstract][Full Text] [Related]
17. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Sep; 79(9):1286-92. PubMed ID: 17607775
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha.
Truong BX; Seo Y; Kato M; Hamano K; Ninomiya T; Katayama M; Kato H; Yano Y; Hayashi Y; Kasuga M
Int J Mol Med; 2005 Aug; 16(2):279-84. PubMed ID: 16012762
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of preS antigen (HBpreSAg) in chronic hepatitis B virus infected patients.
Lian M; Zhou X; Wei L; Qiu S; Zhou T; Li L; Gu X; Luo M; Zheng X
Virol J; 2007 Sep; 4():93. PubMed ID: 17892580
[TBL] [Abstract][Full Text] [Related]
20. Persistence of HBV-DNA in children with chronic hepatitis B who seroconverted to anti-HBs antibodies after interferon-alpha therapy: correlation with specific IgG subclass responses to HBsAg.
Gregorek H; Dzierzanowska-Fangrat K; Woynarowski M; Jóźwiak P; Witkowska-Vogtt E; Socha J; Syczewska M; Madaliński K
J Hepatol; 2005 Apr; 42(4):486-90. PubMed ID: 15763334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
